Aytu BioPharma (NASDAQ:AYTU) & Cocrystal Pharma (NASDAQ:COCP) Financial Analysis

Cocrystal Pharma (NASDAQ:COCP) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Institutional and Insider Ownership

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Comparatively, 6.1% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cocrystal Pharma and Aytu BioPharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	$330,000.00	61.00	-$8.83 million	($0.76)	-1.38
Aytu BioPharma	$57.57 million	0.35	-$14.25 million	($1.66)	-1.11

Cocrystal Pharma has higher earnings, but lower revenue than Aytu BioPharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Cocrystal Pharma and Aytu BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1	0	1	0	2.00
Aytu BioPharma	2	0	2	0	2.00

Aytu BioPharma has a consensus target price of $14.50, suggesting a potential upside of 685.91%. Given Aytu BioPharma’s higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Cocrystal Pharma.

Volatility and Risk

Cocrystal Pharma has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Profitability

This table compares Cocrystal Pharma and Aytu BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Aytu BioPharma	-24.76%	-56.54%	-13.14%

Summary

Aytu BioPharma beats Cocrystal Pharma on 7 of the 13 factors compared between the two stocks.

About Cocrystal Pharma

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

About Aytu BioPharma

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.